Notice: unserialize(): Error at offset 2 of 31 bytes in /data/html/www_bioworld_com/includes/ on line 559 Notice: unserialize(): Error at offset 2753 of 5598 bytes in /data/html/www_bioworld_com/includes/ on line 559 Pharma: Clinic Roundup | BioWorld

Login to Your Account

Pharma: Clinic Roundup

Wednesday, February 22, 2012
• Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, reported top-line results from the GEMINI I Phase III study of vedolizumab in 895 patients with moderately to severely active ulcerative colitis who have failed at least one conventional therapy, including tumor necrosis factor-alpha antagonists. Both phases of the year-long trial met their primary endpoints, providing statistically significant improvements in clinical response in the six-week induction phase and clinical remission in the subsequent maintenance phase.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription